Interaction Checker

Sunitinib interactions

Sunitinib (Sutent) has 271 documented interactions across the FDA labels and fact sheets we index: 3 major, 267 moderate, 1 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (3)

  • BevacizumabMajor

    Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of SUTENT as monotherapy and administered in combination with bevacizumab. (Sunitinib label, Warnings and precautions)

  • Itraconazoleazole antifungalMajor

    Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-­emtansine Vinca alkaloids Not recommended during and 2 weeks after TOLSURA treatment. (Itraconazole label, Drug interactions)

  • Voriconazoleazole antifungalMajor

    Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of voriconazole. (Voriconazole label, Drug interactions)

Moderate interactions (267)

  • AcarboseantidiabeticModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Acebutololbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • AdenosineantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • AlendronatebisphosphonateModerate

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (Sunitinib label, Warnings and precautions)

  • Alfuzosinalpha blockerModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • AliskirenantihypertensiveModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • AlogliptinDPP-4 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Alogliptin and metforminDPP-4 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Amiloridepotassium-sparing diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • AmiodaroneantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • Amitriptylinetricyclic antidepressantModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Amlodipinedihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Amlodipine and atorvastatindihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Amlodipine and benazeprildihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Amlodipine and olmesartandihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Amlodipine and valsartandihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • AnagrelideQT-prolonging drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • AprepitantCYP3A4 inhibitorModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • ArmodafinilCNS stimulantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Arsenic trioxideQT-prolonging drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • AsenapineantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • AtazanavirantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Atenololbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Atenolol and chlorthalidonebeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Azilsartanangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Azithromycinmacrolide antibioticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • BenazeprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Benazepril and hydrochlorothiazideACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Betaxololbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • BexagliflozinSGLT2 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Bisoprololbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Bisoprolol and hydrochlorothiazidebeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • BosentanCYP3A4 inducerModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • CanagliflozinSGLT2 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Candesartanangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Candesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • CaptoprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • CarbamazepineanticonvulsantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Carvedilolbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • CenobamateanticonvulsantModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • ChloroquineantimalarialModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Chlorothiazidethiazide diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • ChlorpromazineantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Chlorthalidonethiazide diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • CimetidineH2 blockerModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • CiprofloxacinfluoroquinoloneModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • CitalopramSSRIModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Clarithromycinmacrolide antibioticModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • ClobazambenzodiazepineModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Clonidinealpha-adrenergic agonistModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • ClozapineantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • CyclosporineimmunosuppressantModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • DapagliflozinSGLT2 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Dapagliflozin and metforminSGLT2 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • DarunavirantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Darunavir and cobicistatantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Deferasiroxiron supplementModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • DeutetrabenazineVMAT2 inhibitorModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • DexamethasonecorticosteroidModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Dextromethorphan and quinidineserotonergic drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Digoxindigitalis glycosideModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • Diltiazemcalcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • DisopyramideantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • DofetilideantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • Doxazosinalpha blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • DronedaroneantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • Droperidoldopamine antagonistModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • DulaglutideGLP-1 receptor agonistModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • EfavirenzantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • EmpagliflozinSGLT2 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Empagliflozin and metforminSGLT2 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • EnalaprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Enalapril and hydrochlorothiazideACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • EnalaprilatACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Eplerenonealdosterone antagonistModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Erythromycinmacrolide antibioticModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • EscitalopramSSRIModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • EslicarbazepineanticonvulsantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Esmololbeta blockerModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • Ethacrynic acidloop diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • EtravirineantiretroviralModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • EverolimusimmunosuppressantModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • ExenatideGLP-1 receptor agonistModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Felodipinedihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • FingolimodimmunosuppressantModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • FlecainideantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • Fluconazoleazole antifungalModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • FluoxetineSSRIModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • FosamprenavirantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • FosaprepitantCYP3A4 inhibitorModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • FosinoprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Fosinopril and hydrochlorothiazideACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • FosphenytoinanticonvulsantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Furosemideloop diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • GlimepiridesulfonylureaModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • GlipizidesulfonylureaModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Glipizide and metforminsulfonylureaModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • GlyburidesulfonylureaModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Glyburide and metforminsulfonylureaModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • GranisetronQT-prolonging drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • GriseofulvinantifungalModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Guanfacinealpha-adrenergic agonistModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • HaloperidolantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • HydralazinevasodilatorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Hydrochlorothiazidethiazide diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • HydroxychloroquineQT-prolonging drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • HydroxyzineantihistamineModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • IbandronatebisphosphonateModerate

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (Sunitinib label, Warnings and precautions)

  • IbutilideantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • IloperidoneantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • ImatinibCYP3A4 inhibitorModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Indapamidethiazide diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Insulin aspartinsulinModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Insulin degludecinsulinModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Insulin detemirinsulinModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Insulin glargineinsulinModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Insulin lisproinsulinModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Insulin regular (human)insulinModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Irbesartanangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Irbesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • IsoniazidantibioticModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Isosorbide dinitrate and hydralazinenitrateModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Isradipinedihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • IvacaftorCYP3A4 inhibitorModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Ketoconazoleazole antifungalModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Labetalolbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • LenacapavirantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • LevofloxacinfluoroquinoloneModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Levothyroxinethyroid hormoneModerate

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (Sunitinib label, Warnings and precautions)

  • Levothyroxine and liothyroninethyroid hormoneModerate

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (Sunitinib label, Warnings and precautions)

  • Lidocainelocal anestheticModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • Lidocaine and prilocainelocal anestheticModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • LinagliptinDPP-4 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Linagliptin and metforminDPP-4 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Liothyroninethyroid hormoneModerate

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (Sunitinib label, Warnings and precautions)

  • LiraglutideGLP-1 receptor agonistModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • LisinoprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Lisinopril and hydrochlorothiazideACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Lofexidinealpha-adrenergic agonistModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • LoperamideQT-prolonging drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • LorlatinibCYP3A4 inducerModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Losartanangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Losartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • MecamylamineantihypertensiveModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • MetforminbiguanideModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • MethadoneopioidModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Methimazoleantithyroid drugModerate

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (Sunitinib label, Warnings and precautions)

  • MethyldopaantihypertensiveModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Metolazonethiazide diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Metoprololbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Metoprolol and hydrochlorothiazidebeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • MexiletineantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • MifepristoneCYP3A4 inhibitorModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • MiglitolantidiabeticModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • MinoxidilvasodilatorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Mirabegronbeta-adrenergic agonistModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • MitapivatCYP3A4 inducerModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • MitotaneCYP3A4 inducerModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • ModafinilCNS stimulantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • MoexiprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • MoxifloxacinfluoroquinoloneModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Nadololbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Nafcillinpenicillin antibioticModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • NateglinidemeglitinideModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Nebivololbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • NefazodoneantidepressantModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • NevirapineantiretroviralModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Nicardipinedihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Nifedipinedihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • NilotinibQT-prolonging drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Nisoldipinedihydropyridine calcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • NitroprussidevasodilatorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • OfloxacinfluoroquinoloneModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Olanzapine and fluoxetineantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Olmesartanangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Olmesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Olmesartan, amlodipine, and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • OndansetronQT-prolonging drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • OxcarbazepineanticonvulsantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • PaliperidoneantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • PamidronatebisphosphonateModerate

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (Sunitinib label, Warnings and precautions)

  • PentamidineQT-prolonging drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • PerampanelanticonvulsantModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • PerindoprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • PhenobarbitalbarbiturateModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Phenoxybenzaminealpha blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Phentermine and topiramateCNS stimulantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • PhenytoinanticonvulsantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • PimavanserinantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • PimozideantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Pindololbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • PioglitazonethiazolidinedioneModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Pioglitazone and glimepiridethiazolidinedioneModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Pioglitazone and metforminthiazolidinedioneModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • PitolisantQT-prolonging drugModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Posaconazoleazole antifungalModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Prazosinalpha blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • PrimidoneanticonvulsantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • ProcainamideantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • PromethazineantihistamineModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Promethazine and codeineopioidModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Promethazine and dextromethorphanantihistamineModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • PropafenoneantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • Propranololbeta blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Propylthiouracilantithyroid drugModerate

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (Sunitinib label, Warnings and precautions)

  • QuetiapineantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • QuinaprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Quinapril and hydrochlorothiazideACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • QuinidineantiarrhythmicModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • QuinineantimalarialModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • RamiprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • RanolazineQT-prolonging drugModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • RepaglinidemeglitinideModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • RifabutinantibioticModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • RifampinantibioticModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • RifapentineantibioticModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • RisedronatebisphosphonateModerate

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (Sunitinib label, Warnings and precautions)

  • RisperidoneantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • RitonavirantiretroviralModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • Sacubitril and valsartanangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • SaxagliptinDPP-4 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Saxagliptin and metforminDPP-4 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • SemaglutideGLP-1 receptor agonistModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • SitagliptinDPP-4 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Sitagliptin and metforminDPP-4 inhibitorModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • SolifenacinanticholinergicModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Sotalolbeta blockerModerate

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (Sunitinib label, Warnings and precautions)

  • Spironolactonealdosterone antagonistModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Spironolactone and hydrochlorothiazidealdosterone antagonistModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Suvorexantsedative-hypnoticModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • SuzetrigineCYP3A4 inducerModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • TacrolimusimmunosuppressantModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Tamoxifenselective estrogen receptor modulatorModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Telmisartanangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Telmisartan and amlodipineangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Telmisartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • TemsirolimusModerate

    Concomitant use of TORISEL with sunitinib The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. (Temsirolimus label, Warnings and precautions)

  • Terazosinalpha blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Teriparatidethyroid hormoneModerate

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (Sunitinib label, Warnings and precautions)

  • TetrabenazineVMAT2 inhibitorModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • ThioridazineantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Ticagrelorantiplatelet agentModerate

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib label, Warnings and precautions)

  • TirzepatideGLP-1 receptor agonistModerate

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (Sunitinib label, Warnings and precautions)

  • Tizanidinemuscle relaxantModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • TolterodineanticholinergicModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • TopiramateanticonvulsantModerate

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (Sunitinib label, Drug interactions)

  • Toremifeneselective estrogen receptor modulatorModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Torsemideloop diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • TramadolopioidModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Tramadol and acetaminophenopioidModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • TrandolaprilACE inhibitorModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • TrazodoneantidepressantModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Triamterenepotassium-sparing diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Triamterene and hydrochlorothiazidepotassium-sparing diureticModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • ValbenazineVMAT2 inhibitorModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Valsartanangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • Valsartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • VardenafilPDE5 inhibitorModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • VenlafaxineSNRIModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Verapamilcalcium channel blockerModerate

    Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib label, Warnings and precautions)

  • ZiprasidoneantipsychoticModerate

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (Sunitinib label, Drug interactions)

  • Zoledronic acidbisphosphonateModerate

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (Sunitinib label, Warnings and precautions)

Minor mentions (1)

  • AxitinibMinor

    MACE occurred in 7% of patients with advanced RCC treated with INLYTA in combination with avelumab compared to 3.4% treated with sunitinib in a randomized trial, JAVELIN Renal 101. (Axitinib label, Warnings and precautions)

Check Sunitinib against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.